Form 4: Alkermes Officer's Planned Share Transactions

Alkermes SVP Christian Todd Nichols reported a pre-planned acquisition of 6,407 ordinary shares and a disposition of 2,845 shares for tax withholding purposes.

Summary

• Christian Todd Nichols, SVP, Chief Commercial Officer of Alkermes plc, reported changes in his beneficial ownership.
• On February 23, 2026, Nichols acquired 6,407 ordinary shares upon the vesting of Restricted Stock Units (RSUs).
• Concurrently, 2,845 ordinary shares were disposed of at a price of $32.19 per share to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Nichols directly beneficially owns 112,762 ordinary shares.
• The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating they were pre-scheduled.
• The Restricted Stock Unit award vests in four equal annual installments, commencing on February 23, 2024.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, reflecting routine executive compensation and tax management rather than a significant change in company prospects or insider sentiment.

Positives

• The acquisition of 6,407 ordinary shares indicates a vesting event for Restricted Stock Units, which is a form of equity compensation for the officer.
• The transaction was pre-planned under a Rule 10b5-1(c) plan, suggesting a structured approach to equity management and reducing concerns about opportunistic trading.

Negatives

• A disposition of 2,845 shares occurred to cover tax withholding, which reduces the officer's direct shareholding, though this is a common practice for RSU vesting.

Future Outlook

The filing indicates future vesting events for the RSU award, as it vests in four equal annual installments commencing 02/23/2024. This implies further share acquisitions and potential tax-related dispositions in subsequent years.

Industry Context

StockSavvy.ai notes that RSU vesting and subsequent tax-related share dispositions are standard practices in executive compensation across the pharmaceutical and biotechnology industries. This type of filing is routine and generally does not signal a change in company fundamentals or management's outlook.

Comparison to Industry Standards

• This type of RSU vesting and tax-related sale is a common compensation mechanism for executives in publicly traded companies, aligning executive incentives with shareholder value over time.
• Similar equity compensation structures are observed at companies like Pfizer, Johnson & Johnson, and Merck, where executives receive performance-based or time-based equity awards that vest over several years, often leading to similar Form 4 filings upon vesting.

Related Party Transactions

• The transactions involve an officer of the company and the company's shares, which is a related party transaction in the context of executive compensation.

Stakeholder Impact

• Shareholders: The disposition of shares for tax purposes slightly increases the float, but the overall impact is minimal given the routine nature of the transaction. The vesting of RSUs aligns executive interests with long-term shareholder value.

Next Steps

• Further vesting installments of the Restricted Stock Unit award are expected annually, commencing on 02/23/2024.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned transaction related to executive equity compensation. It does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. The transaction is neutral in its implications for the stock's fundamental value.

Keywords

Alkermes, ALKS, Form 4, Insider Trading, Beneficial Ownership, Restricted Stock Units, RSU, Equity Compensation, Christian Todd Nichols, SVP Chief Commercial Officer, Rule 10b5-1